How Much Does Testosterone Cypionate Cost in Montana in 2026?

Montana Cash-Pay Pricing Breakdown

The average cash price for a 1 mL vial of generic testosterone cypionate (200 mg/mL) at Montana retail pharmacies sits around $60 per month in 2026. That figure reflects pricing at chains like Walgreens, Albertsons, and independent pharmacies across Billings, Missoula, Great Falls, and Helena.

Manufacturer list price for brand-name Depo-Testosterone hovers near $100 per month, but very few patients pay this. The generic, manufactured by companies like Hikma, Teva, and Sun Pharma, has been available for decades and dominates the market. A 10 mL multi-dose vial of generic testosterone cypionate 200 mg/mL typically costs between $80 and $120 cash-pay and lasts 10 weeks at a standard 200 mg weekly dose, bringing the per-month cost down to roughly $35 to $50 when purchased this way. Pharmacies in smaller Montana towns (Kalispell, Bozeman, Helena) may price slightly higher due to lower dispensing volume, but the difference rarely exceeds $10 to $15 per vial.

The FDA-approved prescribing information for testosterone cypionate lists the standard indication as replacement therapy in males with conditions associated with deficiency or absence of endogenous testosterone. Doses typically range from 50 to 400 mg every two to four weeks, though current clinical practice favors more frequent injections (weekly or twice weekly) at lower per-dose amounts to minimize peaks and troughs [1].

Does Montana Medicaid Cover Testosterone Cypionate?

Montana Medicaid does not cover testosterone cypionate for the diagnosis of male hypogonadism as of 2026. This exclusion applies to both brand and generic formulations.

The omission is not unique to Montana. Several state Medicaid programs exclude testosterone replacement therapy (TRT) entirely or restrict it to narrow diagnostic codes such as Klinefelter syndrome or pituitary failure, excluding the more common "classical" and "functional" hypogonadism diagnoses. Montana's Medicaid formulary categorizes testosterone cypionate as a non-covered injectable androgen for the primary hypogonadism indication. Patients enrolled in Montana Medicaid who have a covered diagnosis (for example, gender-affirming hormone therapy, which falls under a separate coverage pathway) may still access testosterone cypionate, but male hypogonadism alone does not qualify.

For the estimated 6,000 to 10,000 Montana men with clinically diagnosed low testosterone, this means out-of-pocket payment or commercial insurance remains the primary route. The Endocrine Society's 2018 clinical practice guideline recommends testosterone therapy for men with symptomatic hypogonadism confirmed by two morning total testosterone levels below 300 ng/dL, a standard that most Montana prescribers follow [2]. The T-Trials, a coordinated set of seven placebo-controlled trials (N=790 men aged 65 and older), demonstrated that testosterone gel improved sexual function, physical activity, and mood over 12 months, reinforcing the clinical rationale for coverage [3].

Insurance Coverage for TRT in Montana

Most commercial insurance plans available in Montana, including Blue Cross Blue Shield of Montana, PacificSource, and plans sold on the state exchange, cover generic testosterone cypionate with prior authorization. The prior auth process generally requires documentation of two low morning testosterone levels (below 264 to 300 ng/dL depending on the insurer), symptoms of hypogonadism, and the absence of contraindications like untreated polycythemia or active prostate cancer.

Copays under commercial plans with prior authorization approval typically fall between $10 and $30 per month for a generic 1 mL vial. Patients on high-deductible health plans (HDHPs) pay full cash price until the deductible is met, which makes the pricing data above directly relevant. Montana's individual market is dominated by Blue Cross Blue Shield of Montana and PacificSource, both of which list generic testosterone cypionate on their formularies at Tier 2 (preferred generic) after prior authorization.

Dr. Bradley Anawalt, an endocrinologist at the University of Washington and co-author of the Endocrine Society guideline, has noted: "Prior authorization for testosterone therapy is reasonable when it ensures appropriate diagnosis, but it should not create barriers that delay treatment for men with confirmed hypogonadism and debilitating symptoms" [2]. Montana patients denied coverage can appeal through the insurer's internal process and, if necessary, through the Montana Commissioner of Securities and Insurance, which oversees health plan complaints.

A 2020 analysis in the Journal of the Endocrine Society found that prior authorization requirements for testosterone therapy were associated with a 23% reduction in prescription fills among commercially insured men, suggesting that administrative barriers reduce access even when coverage technically exists (Jasuja et al., 2020) [4].

Compounded Testosterone Cypionate in Montana

Compounded testosterone cypionate is legal in Montana when dispensed by a licensed 503A compounding pharmacy with a valid patient-specific prescription. The average price runs about $80 per month, which is higher than the generic retail price but offers customization advantages.

Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications for individual patients based on a prescriber's order. Montana's Board of Pharmacy regulates these pharmacies under Montana Code Annotated Title 37, Chapter 7. Compounding pharmacies in Montana can prepare testosterone cypionate in custom concentrations (for example, 100 mg/mL for patients who need smaller volume injections) and in different carrier oils (grapeseed oil instead of cottonseed oil for patients with allergies).

The tradeoff: compounded products do not undergo FDA review for safety, efficacy, or manufacturing consistency. The FDA's page on compounding warns that compounded drugs "are not FDA-approved" and "may have quality issues" [5]. A 2017 study published in JAMA Internal Medicine tested 12 compounded testosterone products and found that 34.5% failed potency or sterility standards (Gudeman et al., 2013) [6]. Patients choosing compounded testosterone cypionate should verify their pharmacy's accreditation through the Pharmacy Compounding Accreditation Board (PCAB) or a similar body.

Some Montana patients prefer compounded options not for price but for formulation flexibility. Subcutaneous injection protocols using 27- to 30-gauge insulin syringes have grown popular, and compounded preparations in smaller volumes (0.25 mL per dose) make these injections more practical. A 2022 study in the Journal of Clinical Endocrinology & Metabolism found that subcutaneous testosterone cypionate achieved bioequivalent serum levels compared to intramuscular administration with less injection-site pain (Al-Futaisi et al., 2022) [7].

How to Get the Lowest Price in Montana

Six strategies can reduce testosterone cypionate costs for Montana residents paying out of pocket.

Buy the 10 mL multi-dose vial. The per-milligram cost drops 30 to 50% compared to 1 mL single-dose vials. A 10 mL vial of 200 mg/mL generic testosterone cypionate costs $80 to $120 and provides 8 to 10 weeks of therapy at standard doses.

Use a pharmacy discount card. GoodRx, RxSaver, and SingleCare all offer coupons accepted at Montana pharmacies. These can bring the 10 mL vial price to $40 to $70, depending on the pharmacy. Discount cards are not insurance and can be used alongside or instead of insurance.

Compare pharmacy prices. Montana pharmacy pricing varies significantly. Costco pharmacies (membership not required for pharmacy in Montana) and Walmart $4 generics programs tend to offer the lowest retail prices. Independent pharmacies may match or beat chain prices if asked.

Ask about manufacturer savings programs. While no major manufacturer discount card exists specifically for testosterone cypionate generics, some telehealth TRT platforms bundle the medication cost into their subscription fee, effectively providing a discount through bulk purchasing.

Consider telehealth TRT clinics. Telehealth prescribing of testosterone cypionate is legal in Montana. Several national platforms ship testosterone cypionate directly to Montana addresses at bundled monthly prices ranging from $99 to $199, which includes the medication, supplies, and provider consultations. For patients without insurance, this all-inclusive pricing may be simpler than navigating pharmacy costs separately.

Request a 90-day supply. Filling a 90-day prescription at a mail-order or retail pharmacy often reduces the per-dose cost by 10 to 20% compared to monthly fills. Most Montana insurers and discount programs support 90-day fills for maintenance medications like testosterone cypionate.

Clinical Context: When Is TRT Appropriate?

Testosterone replacement is not a cost question alone. The decision to start therapy requires confirmed biochemical and symptomatic hypogonadism.

The Endocrine Society guideline recommends initiating testosterone therapy only in men with unequivocally low morning serum total testosterone on at least two occasions, combined with consistent signs and symptoms (fatigue, reduced libido, erectile dysfunction, decreased muscle mass, depressed mood) [2]. The T-Trials (2016), published in the New England Journal of Medicine, enrolled 790 men aged 65 and older with testosterone levels below 275 ng/dL and at least one symptom domain impairment. After 12 months of testosterone gel vs. placebo, the testosterone group showed significant improvement in sexual desire (P<0.001), erectile function, and 6-minute walk distance [3].

Long-term safety data from the TRAVERSE trial (N=5,246), published in 2023 in the New England Journal of Medicine, demonstrated that testosterone replacement did not increase the incidence of major adverse cardiovascular events (MACE) compared to placebo over a median follow-up of 33 months (hazard ratio 0.99 to 95% CI 0.81 to 1.21) (Lincoff et al., 2023) [8]. This trial addressed a longstanding safety concern that had led the FDA to require a cardiovascular warning on testosterone product labels since 2015.

Monitoring requirements add to the ongoing cost. The Endocrine Society recommends checking hematocrit, PSA, and testosterone levels at 3 to 6 months after initiation, then annually [2]. In Montana, a basic male hormone panel (total testosterone, free testosterone, hematocrit, PSA) costs $50 to $150 out of pocket at labs like Quest Diagnostics or Labcorp, both of which have draw sites in Billings, Missoula, and Great Falls.

Telehealth Access for Montana Residents

Montana permits telehealth prescribing of testosterone cypionate with no in-person visit requirement for established or new patient-provider relationships, provided the prescriber holds an active Montana medical license or practices under the state's telehealth registration pathway.

This is significant for patients in rural Montana. The state spans 147,040 square miles with a population of roughly 1.1 million, and many residents live hours from the nearest endocrinologist. According to the AAFP's workforce data, Montana has fewer than 15 practicing endocrinologists statewide [9]. Telehealth platforms that specialize in TRT fill this access gap by pairing patients with licensed providers who can order labs, evaluate results, write prescriptions, and adjust dosing remotely.

Montana's telehealth parity law (Montana Code Annotated 33-22-138) requires commercial insurers to reimburse telehealth visits at the same rate as in-person visits, which means the consultation cost is often covered under the patient's plan. Patients using cash-pay telehealth TRT services typically pay $99 to $149 per month for the provider relationship, with medication costs either bundled or billed separately.

The American Urological Association's 2018 guideline on testosterone deficiency supports telehealth follow-up for stable TRT patients, noting that "interval monitoring of testosterone levels, hematocrit, and PSA can be effectively managed via telemedicine when the initial evaluation has been conducted thoroughly" (Mulhall et al., 2018) [10].